Timothy Alan Driscoll

Study to Enhance Anti-Neuroblastoma Immune Response in Relapsed/Refractory High-Risk Neuroblastoma Using Nivolumab, Dinutuximab, and Adoptive Transfer of Activated, Allogeneic MHC-1 Mismatched NK Cells

Selected Grants

A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Subjects

Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2020 - 2024

A multicenter study of apheresis collection of peripheral blood mononuclear (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2020

Acid Sphingomyelinase Activation in Apoptosis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2002